Top Abstract Purchase Related
Home
>
Node
>
Subnode

Differential expression of lymphokine-activated killer cells and natural killer cells in adoptive transfer experiments utilizing fractionated bone marrow

Merluzzi, V.J.; Trail, P.A.; Last-Barney, K.

Journal of Immunology 137(8): 2425-2427

1986

ISSN/ISBN: 0022-1767
PMID: 3531332
Document Number: 278903
Precursors of murine natural killer (NK) cells and lymphokine-activated killer (LAK) cells can be distinguished by utilizing an adoptive transfer system in which donor bone marrow is fractionated on Percoll discontinuous gradients. Although precursors of LAK cells are present in all fractions, one fraction (greater than 65% Percoll) contains LAK precursors and is depleted of NK precursors. Both in vitro NK activity and in vivo hybrid resistance is abrogated in recipients of bone marrow from the greater than 65% Percoll fraction, whereas LAK activity can be readily demonstrated.

Document emailed within 1 workday
Secure & encrypted payments

Kanai, T.; Monden, M.; Takeda, T.; Gotoh, M.; Sakon, M.; Umeshita, K.; Hasuike, Y.; Sakita, I.; Nakano, H.; Yoshida, T. 1993: Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2 Gan to Kagaku Ryoho. Cancer and ChemoTherapy 20(11): 1457-1460
Marcus, S.L.; Dutcher, J.P.; Paietta, E.; Ciobanu, N.; Strauman, J.; Wiernik, P.H.; Hutner, S.H.; Frank, O.; Baker, H. 1987: Severe hypovitaminosis C occurring as the result of adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer cells Cancer Research 47(15): 4208-4212
Marincola, F.M.; Da Pozzo, L.F.; Drucker, B.J.; Holder, W.D. 1990: Adoptive immunotherapy of human pancreatic cancer with lymphokine-activated killer cells and interleukin-2 in a nude mouse model Surgery 108(5): 919-929
Vershinina, M.I.; Khalturina, E.O.; Patiutko, I.I.; Zabezhinskiĭ, D.A.; Titov, K.S.; Lebedinskaia, O.V.; Vorob'ev, A.A.; Kiselevskiĭ, M.V.; Kuzovlev, E.N. 2004: Characterization of lymphokine-activated killer cells obtained from the natural killers--T cells of patients with hepatic tumor lesion Vestnik Rossiiskoi Akademii Meditsinskikh Nauk 12: 32-36
Chen, M.F.; Suzuki, H.; Yano, S. 1992: Induction of murine lymphokine-activated killer-like cells by Corynebacterium parvum (C. parvum) in vitro: lysis of tumor cells and macrophages by C. parvum-induced killer cells Anticancer Research 12(2): 451-456
Ueno, Y.; Kohgo, Y.; Sasagawa, Y.; Kanisawa, Y.; Nojiri, S.; Mahara, K.; Niitsu, Y.; Maekawa, S.; Oguma, K.; Urushizaki, I. 1987: A case of pericarditis carcinomatosa showing good response following local transfer of lymphokine-activated killer (LAK) cells Gan to Kagaku Ryoho. Cancer and ChemoTherapy 14(8): 2579-2582
Van'ko, L.V. 1986: Ability of the cells of the regenerating bone marrow to prevent the interaction of natural killer cells with target cells of neoplastic origin Vestnik Akademii Meditsinskikh Nauk SSSR 1986(1): 39-42
Itoh, K.; Tilden, A.B.; Kumagai, K.; Balch, C.M. 1985: Leu-11+ lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL 2)-induced activated killer (AK) cells Journal of Immunology 134(2): 802-807
Shirakawa, F.; Tanaka, Y.; Eto, S.; Suzuki, H.; Yodoi, J.; Yamashita, U. 1986: Effect of interleukin 1 on the expression of interleukin 2 receptor (Tac antigen) on human natural killer cells and natural killer-like cell line (YT cells) Journal of Immunology 137(2): 551-556
Liu, G.R. 1993: Cytotoxicity of human lymphokine-activated killer cells against mitotic phase tumor cells Zhonghua Yi Xue Za Zhi 73(9): 547-548; 576
Ballas, Z.K.; Rasmussen, W. 1987: Lymphokine-activated killer (LAK) cells. III. Characterization of LAK precursors and susceptible target cells within the murine thymus Journal of Immunology 139(10): 3542-3549
Nio, Y.; Zighelboim, J.; Berek, J.S.; Bonavida, B. 1990: Augmentation of cytotoxicity of lymphokine activated killer cells on ovarian tumor cells by various biological response modifiers Anticancer Research 10(2a): 441-446
Fegan, C.; Thomas, H.; Bailey-Wood, R.; Coleman, S.; Phillips, S.; Hoy, T.; Whittaker, J.A. 1995: In vitro LAK (lymphokine activated killer) activity following autologous peripheral blood stem cell is significantly greater than that following autologous bone marrow and allogeneic bone marrow transplantation Bone Marrow Transplantation 16(2): 277-281
Long, G.S.; Cramer, D.V.; Harnaha, J.B.; Hiserodt, J.C. 1990: Lymphokine-activated killer (LAK) cell purging of leukemic bone marrow: range of activity against different hematopoietic neoplasms Bone Marrow Transplantation 6(3): 169-177
Law, K.Seng.; Chen, H-Chang.; Liao, S-Kuei. 2007: Non-cytotoxic and sublethal paclitaxel treatment potentiates the sensitivity of cultured ovarian tumor SKOV-3 cells to lysis by lymphokine-activated killer cells Anticancer Research 27(2): 841-850
Nii, A.; Sone, S.; Okubo, A.; Fawzy, F.; Yanagawa, H.; Ogura, T. 1987: Lymphokine-activated killer (LAK) adoptive immunotherapy: optimal method for large-scale LAK induction Gan to Kagaku Ryoho. Cancer and ChemoTherapy 14(6 Part 1): 1871-1876
Hamada, F.; Fuchimoto, S.; Orita, K. 1989: Suppression of lymphokine activated killer (LAK) cells by immunosuppressive substance Research Communications in Chemical Pathology and Pharmacology 65(1): 81-95
Glassman, A.B. 1989: Interleukin-2 and lymphokine activated killer cells: promises and cautions Annals of Clinical and Laboratory Science 19(1): 51-55
Lynch, D.H.; Miller, R.E. 1990: Induction of murine lymphokine-activated killer cells by recombinant IL-7 Journal of Immunology 145(6): 1983-1990
Ballas, Z.K.; Rasmussen, W. 1990: Lymphokine-activated killer (LAK) cells. IV. Characterization of murine LAK effector subpopulations Journal of Immunology 144(1): 386-395